Back to Directory Christine Chiou Email cchiou@niaid.nih.gov Phone 1-240-292-4181 Institution Division of AIDS Title DAIDS Medical Officer Address 5601 Fishers Lane Room Hoteling Rockville, MD 20852 USA Request an Update Affiliated Studies IMPAACT 2050: CREATE DAIDS Number 39208 Research Area Treatment Study Status Pending IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV DAIDS Number 20721 Research Area Tuberculosis Study Status Closed to Follow Up IMPAACT 2038: Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of Recombinant, Live-Attenuated, Bovine/Human, Parainfluenza Virus Type 3 (B/HPIV3) Vector Vaccines B/HPIV3/RSV/PreF, B/HPIV3/RSV/PreF/TM, or Placebo, Delivered via Nasal Sprayer to HPIV3-Seronegative Children 6 to 24 Months of Age DAIDS Number 39100 Research Area Cure and Immunotherapy Study Status Withdrawn IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Withdrawn IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status Open to Accrual
IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV DAIDS Number 20721 Research Area Tuberculosis Study Status Closed to Follow Up
IMPAACT 2038: Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of Recombinant, Live-Attenuated, Bovine/Human, Parainfluenza Virus Type 3 (B/HPIV3) Vector Vaccines B/HPIV3/RSV/PreF, B/HPIV3/RSV/PreF/TM, or Placebo, Delivered via Nasal Sprayer to HPIV3-Seronegative Children 6 to 24 Months of Age DAIDS Number 39100 Research Area Cure and Immunotherapy Study Status Withdrawn
IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Withdrawn
IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status Open to Accrual